Analysis of potential predictive factors of clinical benefit in patients (pts) with metastatic colorectal cancer (MCRC) treated with single-agent cetuximab as first-line treatment

被引：0
|
作者：
Gravalos, C.
Sastre, J.
Aranda, E.
Massuti, B.
Vega-Villegas, M. E.
Gomez, A.
Varella-Garcia, M.
Jimeno, A.
Diaz-Rubio, E.
Hidalgo, M.
机构：
[1] Hosp 12 Octubre, Madrid, Spain
[2] Hosp Clin San Carlos, Madrid, Spain
[3] Hosp Reina Sofia, Cordoba, Spain
[4] Hosp Gen Univ Alicante, Alicante, Spain
[5] Hosp Univ Marques de Valdecilla, Santander, Spain
[6] Univ Colorado, Hlth Sci Ctr, Aurora, CO USA
[7] Johns Hopkins Univ, Baltimore, MD USA
[8] Hosp Monteprincipe, Madrid, Spain
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2007年 / 25卷 / 18期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4120
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Updated analysis of a phase II study (20060314) of panitumumab (pmab) with FOLFIRI as first-line treatment of patients (pts) with metastatic colorectal cancer (mCRC)
    Greil, R.
    Letocha, H.
    Gamelin, E.
    Thaler, J.
    Hofheinz, R.
    Mineur, L.
    Fernebro, E.
    Karthaus, M.
    Wright, L.
    Koehne, C.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [32] First-line single-agent cetuximab in elderly patients with metastatic colorectal cancer. A phase II clinical and molecular study of the Spanish group for digestive tumor therapy (TTD)
    Sastre, J.
    Aranda, E.
    Gravalos, C.
    Massuti, B.
    Varella-Garcia, M.
    Rivera, F.
    Soler, G.
    Carrato, A.
    Manzano, J. L.
    Diaz-Rubio, E.
    Hidalgo, M.
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2011, 77 (01) : 79 - 85
  • [33] Single-agent capecitabin maintenance therapy after induction of XELOX (or FOLFOX) in first-line treatment of metastatic colorectal cancer
    Xu, R.
    Yuhong, L.
    Huiyan, L.
    Wei, W.
    Zhiqiang, W.
    Xia, Y.
    Dong, M.
    Hua, W. Feng
    Dongsheng, Z.
    Daren, L.
    Chen, L. Yin
    Jun, J.
    Hua, H. Xiao
    Wen, P. Jie
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S373 - S374
  • [34] VEGF GENE POLYMORPHISMS IN THE PREDICTION OF BENEFIT FROM FIRST-LINE FOLFIRI PLUS BEVACIZUMAB (BV) IN METASTATIC COLORECTAL CANCER (MCRC) PATIENTS (PTS)
    Loupakis, F.
    Ruzzo, A.
    Salvatore, L.
    Canestrari, E.
    Cremolini, C.
    Masi, G.
    Schirripa, M.
    Spoto, C.
    Galluccio, N.
    Vincenzi, B.
    Santini, D.
    Bencardino, K.
    Ricci, V
    Catalano, V
    Manzoni, M.
    Danova, M.
    Tonini, G.
    Magnani, M.
    Falcone, A.
    Graziano, F.
    ANNALS OF ONCOLOGY, 2009, 20
  • [35] VEGF gene polymorphisms in the prediction of benefit from first-line FOLFIRI plus bevacizumab (BV) in metastatic colorectal cancer (mCRC) patients (pts)
    Loupakis, F.
    Ruzzo, A.
    Salvatore, L.
    Canestrari, E.
    Cremolini, C.
    Santini, D.
    Bencardino, K.
    Manzoni, M.
    Falcone, A.
    Graziano, F.
    EJC SUPPLEMENTS, 2009, 7 (02): : 357 - 357
  • [36] SIGNIFICANT VARIATION IN FIRST-LINE TREATMENT DURATION AMONG PATIENTS WITH METASTATIC COLORECTAL CANCER (MCRC) TREATED IN THE COMMUNITY SETTING
    Klink, A. J.
    Nabhan, C.
    Ernst, F. R.
    Feinberg, B. A.
    VALUE IN HEALTH, 2017, 20 (05) : A138 - A138
  • [37] Pharmacogenetic analysis in metastatic colorectal cancer (mCRC) patients (pts) treated with second-line irinotecan (IR)+/- cetuximab (CB): The EPIC experience
    Yang, D.
    Pohl, A.
    Zhang, W.
    Lurje, G.
    Ning, Y.
    El-Khoueiry, A.
    Khambata-Ford, S.
    Langer, C.
    Iqbal, S.
    Lenz, H.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [38] Cetuximab as first-line treatment for metastatic colorectal cancer (mCRC): a model-based economic evaluation in Indonesia setting
    Putri, Septiara
    Saldi, Siti Rizny F.
    Khoe, Levina Chandra
    Setiawan, Ery
    Megraini, Amila
    Santatiwongchai, Benjarin
    Nugraha, Ryan R. R.
    Permanasari, Vetty Y. Y.
    Nadjib, Mardiati
    Sastroasmoro, Sudigdo
    Armansyah, Armansyah
    BMC CANCER, 2023, 23 (01)
  • [39] Cetuximab as first-line treatment for metastatic colorectal cancer (mCRC): a model-based economic evaluation in Indonesia setting
    Septiara Putri
    Siti Rizny F. Saldi
    Levina Chandra Khoe
    Ery Setiawan
    Amila Megraini
    Benjarin Santatiwongchai
    Ryan R. Nugraha
    Vetty Y. Permanasari
    Mardiati Nadjib
    Sudigdo Sastroasmoro
    Armansyah Armansyah
    BMC Cancer, 23 (1)
  • [40] CCL2 polymorphism as a predictive marker for bevacizumab (Bev) hi combination with FOLFIRI as first-line treatment in metastatic colorectal cancer (mCRC) patients (pts)
    Siamak, Saadat
    Sunakawa, Yu
    Loupakis, Fotios
    Yang, Dongyun
    Zhang, Wu
    Ning, Yan
    Stintzing, Sebastian
    Stremitzer, Stefan
    Seblo, Ana
    Yamauchi, Shinichi
    Matsusaka, Satoshi
    El-Khoueiry, Rita Elie
    Antoniotti, Carlotta
    Rossini, Daniele
    Cremolini, Chiara
    Falcone, Alfredo
    Lenz, Heinz-Josef
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
12345